The group subsequently conducted another clinical trial, sequentially administering high-dose chemotherapy followed by autologous SCT, CD22- and CD19-CAR T to patients with R/R B-NHL (78). This evidence concerns the gene CD19 and non-Hodgkin lymphoma.